Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Sep 25, 2024 02:26PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
"13.333 Million common shares to ZCC. The Proceeds for continuing oncology clinical development and for RVX apabatelone commercializing efforts"
Same old dog & pony show - help rvx? If they got all of the money they would barely pay off Eversana let alone move the Science forward in any company.
im sick of this slow bleed , the only thing he's taking care of is him self.
I will sell my 100k + shares for a buck Canadian. If anyone wants them PM me & we will get it done.